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Abstract: The cryopyrin-associated syndromes (CAPS) include three autosomal-dominant 
syndromes, that are caused by a mutation in the NLRP3 gene on chromosome 1, encoding the 
cryopyrin protein. These syndromes, familial cold autoinflammatory syndrome, Muckle-Wells 
syndrome  and  neonatal-onset  multisystem  inflammatory  disease,  are  characterized  by 
urticaria-like rash, fever, central nervous system inflammation, an arthropathy and a risk of the 
development of amyloidosis in a respectively escalating degree of severity between the various 
syndromes. Recently the role of cryopyrin in the regulation of interleukin (IL)-1 production and 
activation was described and anti IL-1 therapies were found to be very effective in treating these 
syndromes. There are several types of anti IL-1 medications based on different mechanisms of 
antagonizing IL-1. This paper focuses on the efficacy and safety of canakinumab, a long-acting 
humanized anti IL-1 antibody, in treating these syndromes.
Keywords: canakinumab, cryopyrin-associated periodic syndromes, biologics, treatment, 
autoinflammatory diseases
Introduction to cryopyrin-associated periodic 
syndrome and prevalence
The cryopyrin-associated periodic syndromes (CAPS) include three autosomal-
dominant syndromes, that are caused by a mutation in the NLRP3 (in past also called 
CIAS1/NALP3) gene on chromosome 1, encoding the cryopyrin protein (Table 1a). The 
three syndromes, familial cold autoinflammatory syndrome (FCAS), Muckle-Wells 
syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID), 
are characterized by urticaria-like rash, fever, central nervous system inflammation, 
arthropathy and the risk of later development of amyloidosis(Table 1b, 1c). These 
syndromes are considered variants of the same disease process that vary by severity of 
symptoms, systems involved and outcome.1 All respond dramatically to anti-interleukin 
(IL)-1 therapy.
The prevalence of CAPS in the United States (US) is estimated at about 1/106, 
although there are no formal studies and it is probable there is underdiagnosis of CAPS, 
especially the MWS variant.
Familial cold autoinflammatory syndrome
FCAS (previously called familial cold urticaria), the mildest of the CAPS, was first 
described in 1940 and the genetic mutation discovered in 2001.2,3 Most FCAS patients 
are located in the US and there are probably several hundred patients with this disorder. 
It has been hypothesized that most patients originate from the same family. Almost all 
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Table 1a Genetic characteristics of the cryopyrin-associated periodic syndromes
Disease Inheritance Chromosome Gene defect Protein product Common mutations
FCAS Dominant 1q44 CiAS1/NALP3/NLRP3 Cryopyrin v198M, C259w, R260w
MwS Dominant 1q44 CiAS1/NALP3/NLRP3 Cryopyrin R260w, L, L264v, D303N
NOMiD Dominant 
Sporadic
1q44 CiAS1/NALP3/NLRP3 Cryopyrin C148Q, R168Q, L264F, H,   
RD303H, v351M, L
Genetic mutations are found in only 50% to 70% of patients with MwS and NOMiD.
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patients have a genetic mutation in the NLRP3 gene. FCAS 
often starts at birth and is apparent in 95% of the patients 
by 6 months.
Clinical manifestations4
Typically, the attack starts 2 to 3 hours after generalized 
(not direct contact) cold exposure. Patients develop an 
urticaria-like rash that starts on the extremities and spreads 
to the trunk, low-grade fever, arthralgia, conjunctivitis, 
nausea, extreme thirst, sweating and headaches. The peak 
of the attack occurs at 6 to 8 hours and lasts up to 24 hours. 
The frequency of attacks is variable but can be very frequent 
and debilitating. The rash is not true urticaria (mast cells), 
rather there is a perivascular polymorphonuclear cellular 
infiltrate in the dermis. Amyloidosis is a rare complication 
of FCAS (2% to 4%).
Muckle-Wells syndrome
MWS, the intermediate severity CAPS, was described in 
1962 and the genetic mutation was found together with that of 
FCAS.3,5 MWS starts later in life than FCAS and can appear 
at any age. Most cases are in Europe. Genetic mutations in 
the NLRP3 gene are found in 65% to 75% of patients.
Clinical manifestations6
Attacks are usually not triggered by cold exposure. A typi-
cal attack includes fever, rash, more persistent than in 
FCAS, arthralgia, arthritis, myalgia, headaches, conjunc-
tivitis, episcleritis and uveitis. Attacks last up to 3 days. 
Often starting in adolescence, 50% to 70% of patients 
develop sensorineural hearing loss. Amyloidosis develops 
in 25% of the patients.
Neonatal-onset multisystem 
inflammatory disease
NOMID, termed in Europe chronic infantile neurologic, 
cutaneous, articular syndrome (CINCA), is the most severe 
of the CAPS. First described in 1981, the association with 
the NLRP3 gene was found in 2002.7,8 However, only about 
50% to 60% of patients have mutations in this gene.9
Clinical manifestations1,7,9
The onset of NOMID is at or within several weeks of birth; 
33% to 50% of affected infants are born prematurely. Patients 
present with urticaria-like rash and fever, often occurring 
daily. They also have symptoms related to chronic aseptic 
meningitis such as headaches, irritability and vomiting. 
Table 1b Characteristic of the cryopyrin-associated periodic syndromes
Disease Onset age Typical ethnicity Common triggers Episode duration Interval between 
episodes
FCAS First year of life United States Cold ,24 hours variable
MwS Any age western europe Any 1–3 days variable
NOMiD Birth, infancy Any None Continuous None
Table 1c System involvement of the cryopyrin-associated periodic syndromes
Disease Skin Musculoskeletal Eyes Neurologic
FCAS Urticaria-like Arthralgia Conjunctivitis Headaches
MwS Urticaria-like Arthralgia Conjunctivitis, 
episcleritis, uveitis
Hearing loss, headaches
NOMiD Urticaria-like epiphyseal overgrowth with  
deformities, cartilage  
overgrowth, arthritis
Conjunctivitis,  
uveitis, papillitis
Chronic meningitis, hearing loss,   
mental retardation increased  
intracranial pressure, headaches
Abbreviations: FCAS, familial cold autoinflammatory syndrome; MWS, Muckle-Wells syndrome; NOMID, neonatal-onset multisystem inflammatory disorder.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Late neurologic complications include hydrocephalus, 
developmental delay, mental retardation and hearing loss. 
Eye findings include conjunctivitis, uveitis and papillitis of 
the optic nerve, and may lead to visual loss. By about 2 years, 
50% of patients develop a severe arthropathy, consistently 
mainly of cartilage growth abnormalities leading to severe 
pain, metaphyseal and epiphyseal bony overgrowth, ossifi-
cation irregularities, deformities and disabilities. There is 
little synovial inflammation in NOMID. Patients have typi-
cal morphological changes of short stature, frontal bossing, 
macrocephaly, saddle nose, short, thick extremities with 
clubbing of fingers and wrinkled skin. About 20% die by 
age 20 years and others develop amyloidosis.
Etiology and pathogenesis of CAPS
The three autosomal-dominant syndromes that constitute 
CAPS are caused by single base mutations on the NLRP3 
gene located on the long arm of chromosome 1 encoding the 
protein cryopyrin.1,3,8 Some mutations are specific to one of 
the syndromes and some overlap among all three syndromes 
(Table 1a).1,9 Often, especially in patients with NOMID, no 
mutations are found, thus it is clear that other factors influence 
the development and severity of CAPS.9
The cryopyrin protein contains an N-terminal pyrin 
domain and has an important role in regulation of the 
assembly of the inflammasome, a group of proteins that when 
assembled activate caspase-1 that cleaves pro IL-1β to active 
IL-1β.10 The mutated cryopyrin protein probably increases 
the rate of the inflammasome assembly independently of the 
usual stimuli needed in wild type protein.10,11 Thus the result 
is a gain of function mutation. Cryopyrin is present mainly 
in neutrophil cells and chondrocytes explaining the target 
organs of these diseases.
Management
Non-steroidal anti-inflammatory drugs (NSAIDs) and 
anti-histamine therapies are not effective for FCAS and 
MWS. Corticosteroids may alleviate symptoms but are 
needed frequently and may cause significant adverse effects. 
Anti-IL-1 agents are very effective in alleviating symptoms 
and decreasing inflammation.6,12–18 In recent controlled 
trials, rilonacept a fusion protein soluble IL-1 receptor, and 
canakinumab, a humanized IL-1 antibody, have been shown 
to be effective in treating FCAS and MWS.19,20 In about 
one-third of cases of MWS the hearing loss may be partially 
reversible.21–23
In NOMID, NSAIDs, antihistamines, corticosteroids, 
colchicine, methotrexate and other immunosuppressive 
medications are marginally effective and do not change the 
disease course. One case report showed that etanercept, a 
tumor necrosis factor soluble receptor, was effective, mainly 
for the joints.24
Recent studies have shown the dramatic effect of 
anakinra, a recombinant IL-1 receptor antagonist in treating 
the rash, fever and meningitis of NOMID with normaliza-
tion of the acute phase reactants allowing a reduction in the 
corticosteroid dose.25–28 However, existing joint damage and 
mental retardation was not reversible and many patients 
continue to have increased intracranial pressure despite 
therapy. It appears that early recognition and treatment is 
crucial in preventing long-term damage and disability.
Canakinumab in CAPS – mode  
of action
Canakinumab (ACZ885, Ilaris®; Novartis Pharma) is a 
recombinant, long-acting humanized anti-IL-1β monoclonal 
antibody, which selectively blocks IL-1β. Canakinumab also 
appears to have intracellular effects in addition to its’ primary 
effect as a neutralizing antibody to IL-1. Lachmann et al 
demonstrated that the production of IL-1β, which is mark-
edly increased in CAPS patients (31 ng/day mean production 
examined in 7 patients), was reduced to production levels 
of healthy controls after the administration of canakinumab 
(6 ng/day).29 Thus canakinumab also acts as a negative feed-
back on the production of IL-1β by the inflammasome.30
Pharmacology/pharmacokinetics
Canakinumab binds to serum IL-1β and neutralizes its 
activity by blocking its interaction with IL-1 receptors with 
peak serum concentration occurring approximately 7 days 
after subcutaneous administration of a single, 150 mg dose. 
The range of observed half-life was 21.5 to 33 days31,32 with 
a mean of 26 days.30,31 The absolute bioavailability was 70% 
and the expected accumulation ratio was 1.3-fold following 
6 months of subcutaneous dosing of 150 mg administered 
every 8 weeks. Clearance of canakinumab varied according 
to body weight and was estimated to be 0.174 L/day in a 
CAPS patient weighing 70 kg. There was no indication of 
accelerated clearance or time-dependent change in the phar-
macokinetic properties of canakinumab following repeated 
administration. In pediatric CAPS patients, the peak con-
centrations of canakinumab occurred between 2 to 7 days 
following a single subcutaneous administration of 2 mg/kg 
(max 150 mg) of canakinumab. The half-life ranged from 
22.9 to 25.7 days, similar to the pharmacokinetic properties Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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observed in adults. No gender- or age-related pharmacoki-
netic differences were observed after correction for body 
weight.31
Efficacy/comparative studies
To date there are no published comparative studies, comparing 
canakinumab, anakinra or rilonacept in the treatment of 
CAPS. Lachmann et al published a pivotal, phase III double-
blind, placebo-controlled, randomized withdrawal study of 
canakinumab in patients with CAPS.20 Patients who had 
previously received treatment with anakinra or rilonacept, 
were eligible to participate after a minimal “washout” period 
when treatment was discontinued (different for each anti IL-1 
medication based on half-life) and their disease had relapsed. 
49% of the patients were treated with anakinra before 
entering the study, but there was no data on the efficacy or 
adverse effects of anakinra in these patients. Patients treated 
with canakinumab in previous preliminary trials were also 
allowed to participate when their disease flared.32,33 The study 
was designed as a three-part study. Overall 35 patients were 
enrolled, aged 4 to 75 years, weighing between 15–100 kg. 
It is important to note that the authors did not present details 
on the proportion of patients with each subtype of CAPS. 
In the first part, patients received 150 mg or 2 mg/kg (for 
patients #40 kg) of open label canakinumab by a single, 
subcutaneous injection. Those with a complete response to 
treatment by day 15 who did not flare by the end of 8 weeks 
entered part 2 and were randomly assigned to receive either 
150 mg of canakinumab or placebo every 8 weeks for up 
to 24 weeks. After the completion of part 2 or at the time 
of relapse, whichever occurred first, patients proceeded 
to part 3 and received at least 2 more open-label doses of 
canakinumab.
The primary study outcome measure was the proportion 
of patients in part 2 with a relapse (Table 2) of CAPS 
during canakinumab treatment, as compared with placebo. 
Secondary outcome measures included the proportion 
of patients with a complete response in part 1, the value 
of inflammatory markers (C-reactive protein, serum 
amyloid A), global assessments by physicians and patients 
and safety data. In the open-label first part, the symptoms 
of CAPS started to diminish in all patients within 24 hours 
and 97% of the patients had a complete response by 
day 15. One patient did not maintain complete response 
and two other patients refused randomization and were 
excluded from part 2. Thirty-one patients were random-
ized. During the second part of the study, all 15 patients in 
the canakinumab group remained in remission. In contrast, 
13 of the 16 patients (81%) in the placebo group had a 
disease flare (P , 0.001), within a median of 100 days. The 
inflammatory markers remained within the normal range 
in the canakinumab group, but increased in the placebo 
group. At the final assessment at the end of part 3, a total 
of 30 of the 31 (97%) patients who had entered this part 
of the study had no or minimal disease activity, according 
to the physician’s assessment, and the remaining patient 
had mild disease activity. Rash was absent in 29 of the 
31 patients (94%) and was minimal in the other 2 patients. 
Either no or minimal symptoms were reported by 26 of 
the 31 patients (84%), mild symptoms were reported by 
1 patient, moderate symptoms by 2 patients, and severe 
symptoms by 1 patient, who also had fibromyalgia; data 
were missing for 1 patient.
A later multi-center open-label cohort study enrolled 
a total of 98 patients, including 18 pediatric patients.34 
Fifty-four patients were included from various studies 
of Lachmann et al20,32,33 and 44 were canakinumab-naïve 
patients. The patients received 150 mg or 2 mg/kg (for 
patients #40kg) of canakinumab every 8 weeks by sub-
cutaneous injection. The primary outcome measure was 
to assess the long-term safety but secondary outcomes 
included assessment of response for canakinumab naïve 
patients, the maintenance of response for patients already 
receiving canakinumab and the percentage of patients 
requiring dose adjustment. The complete response for 
canakinumab-naïve patients was defined as in Table 2. A 
complete response was observed in 41 of the 44 canaki-
numab-naïve patients (93.2%). Relapse data were available 
Table 2 Descriptions of response in pivotal and other canakinumab studies in cryopyrin-associated periodic syndromes (CAPS)
Disease activity assessmentsa Rash Laboratory activity markersb
Complete response no or minimal disease activity no or minimal within normal range
Relapse greater than minimal more than minimal above normal range
aDisease activity assessments were performed monthly by physicians who assessed the global disease activity and each of the following symptoms: urticarial rash, arthralgia, 
myalgia, headache, conjunctivitis, fatigue or malaise, and other symptoms related or unrelated to CAPS, The assessments were performed with the use of a 5-point scale. 
bThe values for serum C-reactive protein and serum amyloid A that was within the normal range (,10mg/L for both measures) or defined as relapse when the value for 
either was greater than 30 mg/L.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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for 86% of the patients; 90.6% of these had no relapse, and 
5.9% had experienced at least 1 relapse. At least 1 dose 
adjustment was required by 16.3% of the patients (the dose 
adjustment was not described in the abstract).
In the pediatric subgroup of this study (n = 18; range 5 
to 17 years; 8 adolescents [$12 years]; all were $15 kg), 
11 were naïve to canakinumab and 7 were rolled over from 
Lachmann’s et al study.35 Complete response was achieved in 
9 (81.8%) canakinumab-naïve patients by day 8. The majority 
of canakinumab-treated pediatric patients were relapse free 
(11 out of 18). Three MWS patients experienced 1 relapse, 
3 had missing relapse assessments and 1 MWS/NOMID 
overlap patient did not achieve complete response and the 
dose was uptitrated. Seven children (36.8%) received at least 
1 protocol-defined dose adjustment (first dose doubled) or at 
least 1 frequency adjustment. In other studies of canakinumab 
the median effect of one 150 mg dose of canakinumab was 
127 days.29
As a result of the pivotal study results canakinumab was 
approved by the United States Food and Drug Administration 
in June 2009 for the treatment of FACS and MWS in adults 
and children 4 years of age and older (www.accessdata.fda.
gov/drugsatfda_docs/label/2009/125319s000lbl.pdf), and 
in October 2009 by the European Medicines Agency for use 
in all subtypes of CAPS (www.ema.europa.eu/humandocs/
Humans/EPAR/ilaris/ilaris.htm).
However there are still important questions of efficacy 
not answered by these studies, particularly for MWS and 
NOMID associated with long-term damage. These include 
the prevention of amyloidosis, the prevention of arthropathy 
in NOMID, the prevention of neurologic damage, especially 
hearing loss in MWS and NOMID as well as ocular and 
other central nervous system (CNS) damage related to 
NOMID. Another unanswered question is whether existing 
damage can be reversed including amyloidosis,36 hearing 
loss, CNS function (mental retardation, for example) and 
the arthropathy associated with NOMID. Initial studies in 
anakinra indicate only limited ability to reverse existing 
damage.37
An important issue in answering these questions is 
whether there is adequate penetration of canakinumab to 
the CNS via the blood – brain barrier and whether current 
CNS levels are sufficient to treat these manifestations. As 
we noted, in Lachmann’s studies it was not clear how many 
patients had classic NOMID and whether current doses 
and frequency of administration of canakinumab would be 
sufficient for these patients.
Canakinumab effect on issues 
related to general health, fatigue, 
function and quality of life  
of CAPS patients
Lachmann et al examined issues of general health, fatigue 
and function among the patients in the controlled phase III, 
48 week study.38 Baseline scores for general mental and 
physical health measured by use of the Short-Form (SF)-36® 
and fatigue measured by use of the Functional Assessment 
of Chronic Illness Therapy (FACIT)-Fatigue® questionnaires 
were significantly lower than those expected in the general 
population. Following the first canakinumab dose, SF-36 and 
FACIT-Fatigue® scores improved to the levels expected in 
the general population (time to improvement not described). 
An improvement in functional disability was observed as 
shown by Health Assessment Questionnaire (HAQ) disability 
scores. Health-Related Quality of Life (HRQoL) scores at 
48 weeks were comparable to those observed following the 
first injection, and to the general population, suggesting the 
sustained effect of therapy of canakinumab on primarily 
patient driven outcomes.
Thus, canakinumab for treatment of CAPS has shown 
a rapid and sustained significant impact on important 
physician- and patient-derived outcomes.
Safety and tolerability
Lachmann et al reported no deaths or life-threatening adverse 
effects (AE) in the pivotal study.20 Two patients had serious 
AEs in the open-label part 3, one a urinary tract infection 
requiring hospitalization and the other was an episode of 
vertigo accompanied by acute closed-angle glaucoma. 
Both patients discontinued therapy. Overall 29 (83%) of the 
patients had AEs with 12 (34%) developing infectious AEs. 
There was a significant difference between canakinumab and 
placebo only in the rate of suspected infections (P = 0.03). 
While numbers are small, vertigo was seen solely in canaki-
numab-treated patients with MWS who often have cochlear 
involvement as part of their disease. Table 3 describes the 
AEs seen most frequently in this cohort.
In various publications and abstracts safety data has 
been reported on 102 adult and pediatric patients with 
CAPS exposed to canakinumab.20,29,32–35 These included 
20 patients with FCAS, 72 MWS, 10 MWS/NOMID overlap. 
Sixty-two patients were treated for at least 6 months, 56 for 
at least 1 year and 4 for at least 3 years. A total of 9 seri-
ous AEs were reported. Among these were infections in 
3 patients and vertigo in 2. One of the infections included Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Table  3  Adverse  events  seen  in  more  than  10%  of  patients 
using canakinumab for cryopyrin-associated periodic syndromes: 
controlled study20 (N = 35)
Adverse event N (%)
Nasopharyngitis 12 (34)
Diarrhea 7 (20)
Influenza 6 (17)
Rhinitis 6 (17)
Nausea 4 (14)
Headache 5 (14)
Pharyngitis 5 (14)
weight gain 4 (11)
Musculoskeletal pain 4 (11)
vertigoa 4 (11)
aexclusive to patients with Muckle-wells syndrome.
but the safety profile of all appears similar, with perhaps 
more cases of vertigo and significantly fewer injection-site 
reactions with canakinumab.
Patient satisfaction/acceptability
In general patient satisfaction was remarkable with only 
1 early withdrawal in the controlled study due to lack of 
efficacy. In the placebo withdrawal part of the controlled 
study four patients in the canakinumab group reported having 
severe symptoms associated with other disorders: 2 patients 
in 1 household had acute gastroenteritis, a third patient had 
painful fibromyalgia, and a fourth had migraine headaches. 
The effect on HRQoL was previously reported as well as 
the minimal injection-site reactions. Patients with MWS, 
especially those with hearing loss, need to be aware of the 
potential development of vertigo with treatment.
Conclusions, place in therapy
The efficacy of canakinumab in the treatment of CAPS 
provides proof of concept that IL-1β is an important factor 
in the pathogenesis of this disorder. Canakinumab given 
at 150 mg per dose induced a complete response after the 
administration of a single dose in almost all the patients as 
well as inflammatory markers, and the effect appears to be 
sustained for up to at least 2 months between injections and 
continues to be effective with very little patient drop-out 
for longer periods. Some patients need higher doses (up to 
300 mg) to induce a complete response. HRQoL and general 
mental and physical health and fatigue scores improved to 
the levels expected in the general population. The effect of 
canakinumab was similar in adults and children. To date, 
no deaths or life-threatening AEs have ocurred in CAPS 
patients treated with canakinumab and only mild AEs and 
symptoms were noted, none of which affected continuation 
of treatment. Still, there is a potentially higher risk for sys-
temic infections and perhaps vertigo, especially in patients 
with MWS, which require special attention. The ability to 
administer canakinumab every 2 months with implications 
for compliance and minimal injection-site reactions is also 
attractive.
Other anti IL-1 medications (anakinra and rilonacept) 
also have demonstrated efficacy in CAPS.18,19,28 However, 
the prolonged duration of action of canakinumab and low 
incidence of injection-site reactions may confer certain 
advantages for canakinumab, since both anakinra and 
rilonacept are frequently associated with injection-site 
reactions, and both require more frequent administration 
(daily for anakinra and weekly for rilonacept).18,19,28 However, 
an intra-abdominal abscess following appendectomy. 
As in the controlled study, the most common AEs were 
nasopharyngitis and gastrointestinal disturbance. Other 
common AEs included influenza and headache (actual 
numbers of each AE unavailable from published data). 
There was no change in the AE profile among the longer 
treated patients. One patient discontinued treatment due to 
a potential infection. There were no cases of malignancy 
or opportunistic, including mycobacterium, infections 
reported. Also there were no cases of autoantibody forma-
tion to canakinumab or autoimmune/demyelinating AEs 
reported. No significant differences in safety were noted 
between the adult and pediatric patients.34,35
Injection site and allergic reactions appear to be minimal. 
In parts 1 and 2 of the controlled study 31 patients reported 
having no injection-site reactions; 4 patients reported a 
mild reaction. In part 2, a total of 13 of the 15 patients (87%) 
receiving canakinumab and 15 of the 16 patients (94%) 
receiving placebo reported no injection-site reactions. None 
were severe or led to discontinuation of treatment.
There are no data on safety in pregnancy in humans, 
although in extremely high doses given to marmoset monkeys 
and mice, delays in fetal skeletal development were found. 
No evidence of fetal malformations or embryonic toxicity 
was found in animal studies.
Several safety issues are in need of further investigation. 
Longer-term follow-up of greater numbers of patients is 
necessary. The lack of patients with classic NOMID is also 
noted. While in most cases of CAPS canakinumab is used as 
monotherapy, the safety of canakinumab combined with other 
immunosuppressant medications, used often for NOMID (at 
least prior to the use of anti-IL-1 therapies), may present 
additional safety hazards. The lack of head-to-head studies 
preclude direct comparison of different anti-IL-1 therapies Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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unlike anakinra, there is still a relative lack of data on the 
effect of canakinumab in NOMID, especially on CNS 
manifestations and whether adjustments in doses and fre-
quency are needed. A potential downside of canakinumab 
that has not been demonstrated in studies performed to date 
include the prolonged and profound neutralization of IL-1 
and possible effects on infections or the response of the 
innate immune systems to infections. This issue necessitates 
further safety monitoring in long-term follow-up studies and 
post-marketing registries.
In conclusion, the dramatic role of canakinumab in the 
treatment of CAPS has been well demonstrated, particularly 
in patients with FCAS and MWS.
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